TIDMSLN

RNS Number : 5612M

Silence Therapeutics PLC

09 January 2019

Silence Therapeutics announces departure of Chief Financial Officer

January 9, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces the departure of Mr. David Ellam, its Chief Financial Officer, with immediate effect. Dr Rob Quinn, Silence Therapeutics' Group Head of Financial Planning and Analysis will serve as interim CFO until a new CFO is appointed.

Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

"On behalf of the Board I would like to thank David for his contribution to Silence. He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future."

Enquiries:

 
 Silence Therapeutics plc                          Tel: +44 (0)20 3457 
  Dr David Horn Solomon, Chief Executive Officer    6900 
 Peel Hunt LLP (Nominated Adviser and Broker)      Tel: +44 (0)20 7418 
  James Steel/Oliver Jackson                        8900 
 European IR                                       Tel: +44 (0) 20 
  Consilium Strategic Communications                3709 5700 
  Mary-Jane Elliott / Angela Gray 
  silencetherapeutics@consilium-comms.com 
 US IR                                              Tel: +1 (443) 213-0505 
  Westwicke Partners 
  Peter Vozzo 
  peter.vozzo@westwicke.com

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCDDGDBDXGBGCI

(END) Dow Jones Newswires

January 09, 2019 02:00 ET (07:00 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Silence Therapeutics Charts.
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Silence Therapeutics Charts.